The future of pre-operative joint care isn't about a single solution
We are pleased to announce the launch of HAXL ONE™, our innovative hydrogel technology, and O_CURE®, our platelet-rich plasma (PRP) preparation system.
For more than two decades, we have worked alongside clinicians to provide evidence-based solutions that help patients manage joint pain and maintain mobility. We believe the future of pre-operative joint care lies in access to a range of complementary technologies, each offering distinct mechanisms of action and clinical applications.
That is why we are expanding our musculoskeletal portfolio across three complementary modalities:
- OSTENIL® viscosupplementation
- HAXL ONE™ hydrogel technology
- O_CURE® platelet-rich plasma (PRP)
Together, these technologies provide healthcare professionals with personalised treatment strategies tailored to the individual patient.
HAXL ONE™ contains 88 mg/4.4 ml of cross-linked sodium hyaluronate (20 mg/ml) and is manufactured using SARE Technology®, which combines high- and low-molecular-weight hyaluronic acid to create a stable viscoelastic hydrogel with lubricating and shock-absorbing properties, while enhancing resistance to enzymatic degradation. Developed specifically for the management of moderate osteoarthritis, HAXL ONE™ provides clinicians with an additional treatment option for patients whose clinical needs may extend beyond those typically addressed with traditional viscosupplementation. By complementing our established OSTENIL® range, which supports patients with mild to moderate osteoarthritis, HAXL ONE™ helps broaden the treatment pathway available to healthcare professionals managing patients across different stages of disease progression.
Complementing this approach, O_CURE® is a PRP preparation system engineered to deliver a highly concentrated platelet product with a B-B-A DEPA classification, reflecting platelet dose, recovery efficiency, blood cell purity and activation status. Through a proprietary preparation process designed to minimise cellular stress, adhesion and aggregation, O_CURE® helps preserve platelet integrity and supports a standardised, high-quality PRP preparation.
Ben Taylor Dingwall, Managing Director of TRB Chemedica UK, commented:
"The future of pre-operative joint care isn't about a single solution. Every patient presents differently, and clinicians need access to a range of treatment options that support personalised care and informed decision-making.With the launch of HAXL ONE™ and O_CURE®, we're expanding our portfolio beyond viscosupplementation alone and strengthening our commitment to supporting healthcare professionals across the entire joint care pathway. By bringing together viscosupplements, hydrogels and PRP preparation technologies, we're providing clinicians with a broader toolkit to help patients remain active."
As part of the Swiss-based TRB Chemedica Group, we continue to invest in innovative technologies that complement our established musculoskeletal portfolio and support evolving approaches to patient care. The launches of HAXL ONE™ and O_CURE® reflect our ongoing commitment to scientific excellence, clinician education and meaningful innovation that addresses real-world clinical needs.
As healthcare professionals increasingly seek personalised approaches to managing osteoarthritis and joint pain, we believe the future lies not in a single product or modality, but in providing access to a range of evidence-based solutions that can be tailored to individual patients.